Are we getting closer to understanding why we get prostate cancer?

Every so often we note that we still have little to no really clear idea why men get prostate cancer in the first place (or indeed why any of us get any type of cancer). In this context, some new research from a team at the University of California, Los Angeles, is at least interesting. … READ MORE …

A better way to identify risk for metastasis?

According to a news report on the ScienceDaily web site, researchers in the UK have identified a subgroup of circulating tumor cells (CTCs) in patient’s blood that seem to be linked to risk for progression and spread of prostate cancer. … READ MORE …

A new method to use CTCs to diagnose/assess risk for prostate cancer?

In another breaking story from the UK, a company called Angle PLC has announced that its Parsortix diagnostic system can potentially be used to identify men with prostate cancer using a simple blood sample and testing for the presence of circulating tumor cells (CTCs). … READ MORE …

Of liquid biopsies, CTCs, and first-line treatment for mCRPC

A paper to be presented at the Genitourinary Cancers Synposium today, suggests that use of a liquid biopsy and analysis of single circulating tumor cells (CTCs) may be helpful in determining therapy for men with metastatic, castration-resistant prostate cancer (mCRPC). … READ MORE …

Liquid biopsies and CTC assays — the scientific progress continues

A paper in the British Journal of Cancer has offered further validation of the potential roles for liquid biopsies and circulating tumor cells (CTCs) in the management of aggressive forms of prostate cancer (and in related clinical trials). … READ MORE …

Can Cytori Cell Therapy change the way we treat long-term male incontinence post-surgery?

What is described as an open-label, multi-center, single-arm study (the ADRESU trial) has opened in Japan to evaluate the efficacy and safety of periurethral injection of autologous adipose-derived regenerative cells (ADRCs) for the treatment of male stress urinary incontinence resulting from radical prostatectomy (or from transurethral resction of the prostate). … READ MORE …

Use of CTCs to assess response to abiraterone acetate at 12 weeks on therapy

Back in 2011 we reported a presentation by Scher et al. indicating that circulating tumor cell counts (CTCs) could probably be used to monitor responses to abiraterone acetate (and perhaps other forms of drug therapy) in the treatment of men with metastatic, castration-resistant prostate cancer. … READ MORE …